Aptose Story

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;'>AB</div>
APTO -- USA Stock  

USD 5.48  0.27  5.18%

Aptose Bioscns is scheduled to announce its earnings today. The next earnings report is expected on the 4th of May 2021. Aptose Bioscns Market Capitalization is quite stable at the moment as compared to the past year. The company's current value of Market Capitalization is estimated at 390.36 Million. Tangible Asset Value is expected to rise to about 124.7 M this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to (23.7 M). Although many aggressive traders are getting into healthcare space, Aptose Bioscns may or may not be your first choice. We will analyze why Aptose Bioscns investors may still consider a stake in the business.
Published over three weeks ago
View all stories for Aptose Bioscns | View All Stories
Thinking to trade Aptose (NASDAQ:APTO) based on its current debt commitments?
This firm currently holds 1.2 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the firm is not taking enough advantage from borrowing.
The firm shows a Beta (market volatility) of 0.7015, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Aptose's beta means in this case. As returns on the market increase, Aptose Bioscns returns are expected to increase less than the market. However, during the bear market, the loss on holding Aptose Bioscns will be expected to be smaller as well. Even though it is essential to pay attention to Aptose Bioscns historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards foreseeing any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Aptose Bioscns exposes twenty-seven different technical indicators, which can help you to evaluate its performance. Aptose Bioscns has an expected return of -0.18%. Please be advised to confirm Aptose Bioscns value at risk, as well as the relationship between the skewness and day median price to decide if Aptose Bioscns stock performance from the past will be repeated at some point in the near future.
Aptose Bioscns financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Aptose Bioscns, including all of Aptose Bioscns's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Aptose Bioscns assets, the company is considered highly leveraged. Understanding the composition and structure of overall Aptose Bioscns debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it.
Please read more on our technical analysis page.

Understanding Aptose Total Debt

Aptose Bioscns liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Aptose Bioscns has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Aptose Bioscns balance sheet include debt obligations and money owed to different Aptose Bioscns vendors, workers, and loan providers. Below is the chart of Aptose main long-term debt accounts currently reported on its balance sheet.
You can use Aptose Bioscns financial leverage analysis tool to get a better grip on understanding its financial position

How important is Aptose Bioscns's Liquidity

Aptose Bioscns financial leverage refers to using borrowed capital as a funding source to finance Aptose Bioscns ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Aptose Bioscns financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Aptose Bioscns's total debt and its cash.

Acquisition by Bejar Rafael of 343000 shares of Aptose Biosciences subject to Rule 16b-3

Legal trades by Aptose Bioscns insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Aptose insider trading alert for grant of employee stock option (right to buy) by Bejar Rafael, Sr. VP Chief Medical Officer, on 6th of January 2021. This event was filed by Aptose Biosciences Inc with SEC on 2021-01-06. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Detailed Perspective On Aptose Bioscns

The company reported the previous year's revenue of 19.72 M. Net Loss for the year was (48.23 M) with profit before overhead, payroll, taxes, and interest of 0.

Asset Breakdown

Total Assets124.67 Million
Current Assets122.55 Million
Assets Non Current2.12 Million

Does Aptose Bioscns have cash to continue?

The potential upside is down to 5.39 as of today. Aptose Bioscns exhibits very low volatility with skewness of 0.08 and kurtosis of 0.1. However, we advise investors to further study Aptose Bioscns technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Aptose Bioscns' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Aptose Bioscns' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

The Current Takeaway on Aptose Bioscns Investment

Whereas some firms in the biotechnology industry are either recovering or due for a correction, Aptose Bioscns may not be performing as strong as the other in terms of long-term growth potentials. While some institutional investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Aptose Bioscns.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Aptose Bioscns. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com